- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03386305
Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant
A Randomized Controlled Trial to Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main aim of this study is to assess the immunosuppressant adherence, efficacy, and safety in post liver transplant patients converted from twice daily tacro to once daily EnvarsusXR. Tacrolimus trough level, clinical markers of liver disease, HbA1c , eGFR will be assessed at baseline, 1 week, 2 week, 4 week, 3 month and 6 months. Graft rejection will be assessed using routine standard guidelines to identify the cause. All patients post 1 year liver transplant, and within 5 years will be eligible to participate.
The primary hypothesis is that once daily dosing will improve medication adherence in patients randomized to the test arm as compared to the control arm, over a period of 9 months. The clinical efficacy will be assessed by no difference in standard deviation of tacrolimus in the two groups. The secondary hypothesis is that improved medication adherence will lead to improved patient reported quality of life (as assessed by PROMIS-29), and better health outcomes (as assessed by HbA1c, eGFR).
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19141
- Einstein Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who are 1 year post liver transplant, but within 5 years of transplant
- Serum Creatinine<= 2.5 mg/dl; AST,ALT, AP and GGT<=2 times ULN
- Patient must be on a stable tacrolimus dose, with tacrolimus trough levels between 5-12 ng/ml for 4 or more weeks before enrolment
Exclusion Criteria:
- Cognitive impairment which precludes participation
- Projected survival, in the opinion of the provider, of less than three months
- Any other solid organ transplant (kidney or pancreas)
- Use of any drug which is known to interfere with tacrolimus metabolism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EnvarsusXR arm
Patients are converted to once daily EnvarsusXR (study drug).
The patients continue taking this medication for 9 months of the study.
Initial dosage will be 0.8 times the total daily dose of tacro bid, due to higher bioavailability.
All subsequent dose adjustments will be based on maintenance of target tacro trough levels within range of 5-12 ng/ml.
|
Patients randomized to study drug will be converted to EnvarsusXR once daily.
Other Names:
|
Active Comparator: Standard of care arm
Post Liver Transplant patients take Tacrolimus twice daily as a part of standard of care.
Those participating in the study will continue to take tacrolimus twice daily, as apart of their regular care.
As a part of the study, they will complete the medication adherence and quality of life instruments.
|
Patients continue to take Tacrolimus BID, as a part of routine care.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Medication Adherence
Time Frame: From baseline to 6 months
|
Self reported using BAASIS instrument.
BAASIS measures taking, skipping and dose reduction of drugs, with a recall period of 4 weeks.
It consists of 4 questions with a 6 point response scale (ranging from never to every day).
An additional overall adherence is ranked on a scale of 0 to 100 using a visual analog scale.
|
From baseline to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quality of life
Time Frame: From baseline to 6 months
|
Self reported, using PROMIS-29.
PROMIS is a result of the NIH support to develop a "psychometrically validated, dynamic system to measure QOL and patient reported outcomes in study participants.
PROMIS-29 comprises a set of 29 questions evaluating seven QOL domains: Physical function, anxiety, depression, fatigue, sleep disturbance, social function and pain.
The scores are reported as a T score (mean 50, SD=10) centered on the sample representative of 2000 US general census considering demographic variables.
|
From baseline to 6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Manisha Verma, MBBS, MPH, Einstein Healthcare Network
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5024
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post Liver Transplant
-
Fudan UniversityActive, not recruitingHBV | POST LIVER TRANSPLANTChina
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation in ChildrenCompletedLiver Transplant | Kidney Transplant | Heart Transplant | EBV-Related PTLD | Small Intestine Transplant | PTLDsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Inonu UniversityRecruitingLiver Failure | Liver Transplant; Complications | Post Operative PainTurkey
-
Oslo University HospitalSouth-Eastern Norway Regional Health AuthorityNot yet recruitingLiver Metastases | Liver Transplant; Complications | Liver Cancer | Transplant | Transplant; Failure, Liver | Transplant; Complication, Rejection | Transplant Dysfunction
-
Boston Scientific CorporationCompletedAnastomotic Biliary Stricture Post Orthotopic Liver TransplantUnited States
-
University Health Network, TorontoNot yet recruitingSolid Organ Transplant | Liver Transplant | Kidney Transplant | Heart Transplant
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)TerminatedLiver Transplant | Kidney TransplantUnited States
-
Astellas Pharma Europe Ltd.CompletedLiver Transplant | Kidney TransplantItaly, Spain, Belgium, Germany, Latvia, Canada, Korea, Republic of, Czechia, Austria, Finland, Belarus, Estonia, France, Hungary, Ireland, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Sweden, Switzerland, United...
-
Memorial Bahçelievler HospitalCompletedLiver Diseases | Liver Failure | Liver Cirrhosis | Liver Transplant; Complications | Liver Transplant Rejection | Organ Transplant Failure or Rejection | Liver Transplant FailureTurkey